Molecular oncogenesis Flashcards

1
Q

Genes whose normal function is to REDUCE genomic instability

A

Tumor supressors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Functions normally to SLOW cell growth (and/or repair DNA). Thus tumor cells want these genes INACTIVATED

A

Tumor supressors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Oncogenes

A

Genes which, when activated (by mutation, virus etc.), increase the propensity for genomic instability

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Functions normally to PROMOTE cell growth. Thus cancer wants these genes ACTIVATED.

A

Oncogenes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Testing for tumor suppressor mutation

A

Test must assay global gene function. PCR for microsatellite instability or be prepared to find nearly any possible mutation. Full gene sequencing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

IN GENERAL, BOTH COPIES OF A ______________ MUST BE INACTIVATED FOR A CANCER CELL TO BENEFIT!

A

Tumor suppressor (mutations that activate tumor suppressors do not cause cancer)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Testing for oncogene mutations

A

Global function testing, targeted PCR or sequencing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Difficult for cancer to make a better version of oncogenes so cancer makes mutations that _______ oncogenes.

A

up-regulate oncogenes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Oncogenes: High peak on 4-D graph=

A

strong advantage for cancer cell (up-regulate oncogenes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Tumor suppressors: Valley on 4-D graph=

A

strong advantage for cancer cell (down-regulate tumor suppressors)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

True or false? You will never see cancers with mutations that inactivate (valleys) oncogenes.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

single most most common genetic alteration in human tumors?

A

p53 tumor suppressor (over 50% have mutation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

p53 function

A
  • regulates G1–>S
  • cell cycle arrest
  • triggers apoptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

p53 mutation 80% are what kind of mutation and where?

A

point mutation on DNA binding region (this is an example of MICRO instability)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Interference with protein function creating a functional (but not QUANTITATIVE) deficiency. Name an example of actual quantitative deficiency.

A

E6 protein of HPV binds p53 and promotes degradation.

NOTE: remember it is E7 of HPV that binds to and inactivates RB for increased G1–>S phase transition

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Li-Fraumeni Syndrome:

A
  • Knudson’s Two Hit Hypothesis (just like RB)
  • One inherited INACTIVATING mutation in p53
  • Acquired second hit in only good copy of p53 triggers the actual tumor
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Li-Fraumeni Syndrome: Predisposes individual to what?

A

-Tumors at a young age (

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

APC (Adenomatous polyposis coli) gene

A
  • Tumor suppressor gene

- Down-regulate growth-promoting signal of B-catenin!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Familial adenomatous polyposis (FAP)

A
  • One defective germ-line mutation of APC
  • Thousands of colon polyps
  • Cancer with second APC gene mutation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Sporadic colon cancer: 70-80% homozygous loss of what gene?

A

APC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Functions of Beta-Catenin

A
  • Enters nucleus and up-regulates cell cycle genes

- Attached to E-CADHERIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

E-Cadherin

A

-Cell surface protein for intercellular adhesion for Beta-Catenin

23
Q

What disrupts e-cadherin and frees β-catenin to enter nucleus?

A

Loss of cell-cell contact

24
Q

APC Defect:

A

-β-catenin is not broken down

Remember: APC is a tumor suppressor-takes 2

25
Q

β-catenin mutation creates resistance to what?

A

-resistance to APC

Remember: β-catenin is an oncogene-only 1

26
Q

E-cadherin defect frees β-catenin. Functional APC can still handle this–unless….

A

unless WNT is activated, blocking APC function

27
Q

WNT mutations block APC inhibition of

A

β-catenin

-This will work like an oncogene

28
Q

Tumor Suppressor Genes with hereditary syndromes: INK4a/ARF

A

Familial melanoma

29
Q

Tumor Suppressor Genes with hereditary syndromes:

TGF-β Pathway

A

eg pancreas

30
Q

Tumor Suppressor Genes with hereditary syndromes: PTEN

A

Cowden syndrome

31
Q

Tumor Suppressor Genes with hereditary syndromes: NF1

A

Neurofibromatosis type 1

32
Q

Tumor Suppressor Genes with hereditary syndromes: NF2

A

Neurofibromatosis type 2

33
Q

Tumor Suppressor Genes with hereditary syndromes: VHL

A

von Hippel-Lindau Syndrome

34
Q

Tumor Suppressor Genes with hereditary syndromes: WT1/2

A

Wilms tumor

35
Q

Tumor Suppressor Genes with hereditary syndromes: PTCH (Patched)

A

Nevoid basal cell carcinoma syndrome

36
Q

Tyrosine kinase receptor

A
  • example of an oncogene that is a growth factor receptor

- Cell continues to be divide without growth factor

37
Q

TKI

A

Tyrosine kinase inhibitors (TKI) used for therapy

38
Q

RET gene

A
  • example of an oncogene that is a growth factor receptor

- Cell survival in neuroendocrine cells

39
Q

Multiple Endocrine Neoplasia (MEN) 2A: Germline (hereditary) extracellular region mutation. What oncogene is mutated? What cancers can result?

A

-RET
Medullary thyroid carcinoma
Parathyroid (not seen in MEN 2B)
Adrenal

40
Q

MEN 2B is an intra/or extracellular mutation of RET gene?

A

INTRACELLULAR

41
Q

Gastrointestinal stromal tumor (GIST)

A
  • C-kit gene (oncogene for GF receptor)

- Treat with tyrosine kinase inhibitor Imatinib (Gleevec)

42
Q

Chronic myelomonocytic leukemia (CMML):

A
  • t(5;12) PDGF receptor (PDGFR) cytoplasmic domain fused with TEL transcription factor
  • PDGFR active without stimulus (still a Tyrosine Kinase receptor don’t be dumb)
43
Q

BCR-ABL fusion gene

A
  • t(9;22) with BCR from 22 and ABL from 9 (Philadelphia Chromosome)
  • The Philly trucker says “breaker-able 9 22”
  • NOT a cell surface protein (still involved in signal transduction)
  • BCR constitutively activates ABL tyrosine kinase
44
Q

Break point (BCR-ABL): Major (“M”)

A

Chronic myleogenous leukemia (CML); few cases acute lymphocytic leukemia (ALL)

45
Q

Break point (BCR-ABL): Minor (“m”)

A

Usually acute lymphocytic leukemia (ALL)

46
Q

Imatinib mesylate (Gleevec):

A

Designer drug inhibits BCR-ABL tyrosine kinase

47
Q

Example of an oncogene (that is a receptor for GF) that can be over expressed. Increased numbers of NORMAL growth factor receptor (protein structure is NOT altered)

A

ERBB2 (Her-2/neu) overexpressed in breast cancers

48
Q

Treatment for ERBB2 (Her-2/neu) overexpressed in breast cancers

A

Treat with Trastuzumab (Herceptin)

49
Q

EGFR (oncogene)

A
  • Activated in certain carcinomas
  • Lung and colon especially
  • Upregulated in some forms of glioblastoma
50
Q

What can EGFR be targeted by?

A
  • Can be targeted by erlotinib, cetuximab

- Generally works ONLY if activating mutations further down the chain are NOT present

51
Q

KRAS (oncogene)

A
  • Glycine residues at codons 12 and 13

- Early, common mutation in GI and pancreatic tumors, among others

52
Q

NRAS, HRAS

A
  • Codon 61

- More common than KRAS in thyroid neoplasms

53
Q

PI3KCA

A
  • Associations with breast, lung, colon, gynecologic cancers

- Targeted therapies in late phase III trials

54
Q

BRAFF

A
  • V600E mutation
  • Common in thyroid, melanoma, colon (50% of sporadic cancers) etc.
  • Targeted therapy for codon 600 mutations approved for metastatic melanoma